Structural insights into the inhibition of Zika virus NS2B-NS3 protease by a small-molecule inhibitor. Structure, 26 (4). These authors contributed equally to the work;
Introduction
Zika virus (ZIKV) is a mosquito-borne pathogen and a member of the Flaviviridae family which also includes other important human pathogens such as Dengue virus (DENV), West Nile virus (WNV), yellow fever virus, Murray Valley encephalitis virus, and Japanese encephalitis virus. The recent outbreak of ZIKV has threatened global populations. ZIKV infection is found to be related to neurological disorders such as Guillain-Barré syndrome, acute myelitis (Broutet et al., 2016; Petersen et al., 2016) and microcephaly (Ndeffo-Mbah et al., 2016) . Therefore, effective strategies such as vaccines and antivirals are urgently needed. Effort has been made to develop chemical therapies against its close pathogens such as DENV and WNV (Jones et al., 2015; Luo et al., 2015) , but there are still no clinically approved antivirals available.
The ZIKV genome encodes a polyprotein that can be post-translationally processed by both host signal peptidases and viral protease into three structural proteins (C, prM, and E) required for viral particle assembly and seven non-structural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5) required for viral replication and virion assembly. The viral protease is a two-component serine protease formed by the N-terminal part of NS3 and the cofactor region of NS2B-a membrane protein essential for the membrane location of NS3 (Baronti et al., 2014; Clum et al., 1997; Li et al., 2015) . This two-component complex forms an active site with a catalytic triad composed of H51, D75, and S135 Zhang et al., 2016) . The viral protease cleaves the junctions of NS2A/NS2B, NS2B/NS3, NS3/NS4A, and NS4B/NS5 to release functional proteins. Structural studies have demonstrated that the protease recognizes the sites composed of positive charged residues such as R and K at the P1 and P2 positions, respectively (Lei et al., 2016; Phoo et al., 2016) . The negative charges at the protease active site make it challenging to develop small molecule substrate competitive inhibitors (Kang et al., 2017; Poulsen et al., 2014) .
Different approaches such as high-throughput screening (HTS), structure-based drug design, substratebased inhibition, and in silico docking have been used to develop DENV and WNV protease inhibitors (Deng et al., 2012; Lim and Shi, 2013; Nitsche et al., 2012; Yang et al., 2011; Yin et al., 2006) . Although no DENV or WNV protease inhibitor has entered clinical stages, some of the available inhibitors have been shown to be active against ZIKV protease (Lei et al., 2016; Li et al., 2017b) . This is not surprising because DENV, WNV, and ZIKV proteases share high structure similarities (Kang et al., 2017) .
The structure of ZIKV NS2B-NS3 protease is almost identical to those of DENV and WNV proteases (Chen et al., 2016; Erbel et al., 2006; Lei et al., 2016; Phoo et al., 2016; Zhang et al., 2016) . We have used an unlinked ZIKV protease construct (designated as bZiPro) for structural and inhibitor binding studies (Li et al., 2017a; Li et al., 2017b; Phoo et al., 2016; Zhang et al., 2016) . Although conformational exchanges exist in bZiPro, it is dominantly in the closed conformation and is more suitable for structural and ligand binding studies than the conventional linked construct (Kang et al., 2017; Li et al., 2017a) . Structural information for ZIKV protease in complex with several inhibitors is available, which supports antiviral inhibitor design (Lei et al., 2016; Phoo et al., 2016; Zhang et al., 2016) . Peptidic inhibitors such as Ac-Lys-Arg-H derived from protease substrates are potent competitive inhibitors, but it is very challenging to develop them into drug-like molecules due to issues such as cell penetration and stability (Li et al., 2017b) , which has stimulated the search for new inhibitors (Luo et al., 2015; Nitsche et al., 2014b) . Small molecule inhibitors are of great interest. To date, there is only one structure available for ZIKV protease in complex with a non-pepditic chemical fragment is available . Lack of ZIKV protease structures in complex with small molecular weight inhibitors limits the understanding of the molecular interaction and structure-based drug design . Pyrazole ester derivatives are active against both WNV and DENV proteases and identified from a HTS of a small molecule library from NIH (Johnston et al., 2007) .
This type of inhibitors are unstable in solution (Sidique et al., 2009) and have been shown to covalently link to DENV protease (Koh-Stenta et al., 2015) . However, the structural information of the complex is not well described due to the difficulty in structural studies (Koh-Stenta et al., 2015) .
In this study, we demonstrate that bZiPro forms a covalent complex with one pyrazole ester derivative, 5amino-1-((4-methoxyphenyl)sulfonyl)-1H-pyrazol-3-yl benzoate (compound 1) evidenced by the mass spectrometry. We then solved the crystal structure of bZiPro in complex with compound 1, which reveals that the benzoyl moiety of the inhibitor forms a covalent bond with S135 of NS3. The remaining hydroxylpyrazole moiety from compound 1 is released into the media and is not found bound to the protease, which is also verified by NMR binding study. The crosslinked benzoyl group further stabilizes the closed conformation of bZiPro as NMR signals of most residues from both NS2B and NS3 are well resolved.
Further binding study demonstrated that the integrity of the compound is critical for protease binding as the fragments derived from compound 1 exhibited no interaction with bZiPro. Compound 5, a derivative of compound 1, interacts similarly with and inhibits bZiPro strongly. Our study provides the structural information of ZIKV protease in complex with a covalent small molecule to understand the covalent interactions. Our current study is therefore useful for structure-based design of ZIKV protease inhibitors.
Results

Compound 1 reacts with ZIKV NS2B-NS3 protease
Compound 1 was considered as an allosteric inhibitor of WNV NS2B-NS3 protease (Sidique et al., 2009) and a further study has shown that it forms covalent interactions with DENV protease (Koh-Stenta et al., 2015) ( Fig. 1A) . We found that compound 1 inhibits the enzymatic activity of bZiPro with an IC 50 of 1.5 µM when Benzoyl-Nle-Lys-Arg-Arg-aminomethylcoumarin (Bz-nKRR-AMC) was used as a substrate. bZiPro exhibited a 104 Da molecular weight increase in the ESI-TOF MS spectrum after treatment with compound 1 (Fig. 1B) , mirroring the results from DENV protease and indicating the modification of bZiPro by the benzoyl moiety based on the structure of compound 1 (Koh-Stenta et al., 2015) (Fig. 1C) . The ester group in the inhibitor makes compound 1 unstable in solution, giving rise to production of the benzoic acid and 5-amino-1-((4-methoxyphenyl)sulfonyl)-1H-pyrazol-3-ol (compound 2) (Sidique et al., 2009 ).
Crystal structure of bZiPro (C143S)-compound 1 complex
Zika protease is able to form a dimer and a disulfide bond between C143 residues of neighboring NS3 in the crystal was observed (Kang et al., 2017) . To remove the crystallographic disulfide bond of C143, A C143S mutation was generated and the resulting mutant has little influence on the protease activity ( Figure S1 ). We determined the crystal structure of bZiPro (C143S)-compound 1 complex at a resolution of 1.9 Å (Fig. 2, Table 1 ). The four protease molecules in one unit cell were labeled following the peptide chain IDs ( Figure S1 ). Consistent with the MS result, the benzoyl moiety of compound 1 forms a covalent bond with the side chain of S135. The benzoyl moiety sits in the S1 pocket and overlays with the aliphatic chain of the P1 residue of the Ac-Lys-Arg-H inhibitor (Fig. 2) . Atoms of several residues are in close contact (less than 5 Å) with the benzoyl moiety. There is one hydrogen bond formed between the oxygen atom and the nitrogen atom of the side chain of H51, which may be critical for the closed conformation of the complex (Fig. 2) . The benzoyl moiety of the compound 1 also forms π-π stacking interactions between Y161 and A132. The compound 1 does not have molecular interactions with the backbone amide protons of G133 and T134. The oxyanion hole is also not formed due to the cis conformation of the A132-G133 peptide bond (Fig. 2B) . The remaining portion (compound 2) of compound 1 is not present in the structure, suggesting its release from the active site upon trans-esterification reaction by S135. Unlike the NS2B-NS3 cleavage site peptide, Thr-Gly-Lys-Arg (TGKR) and other inhibitors, benzoyl moiety does not form any interaction with residues of NS2B, suggesting that the occupancy of the S1 pocket alone is sufficient for suppressing the open conformation of protease .
Crystal structure of bZiPro (C143S)-Ac-Lys-Arg-H complex
We also determined the crystal structure of bZiPro (C143S)-Ac-Lys-Arg-H complex to a high resolution of 1.51 Å with Rwork and Rfree values of 18.78 % and 20.16 % respectively ( Fig. 3 , Table 1 ). The protease in the complex adopts a very similar structure to the WT reported recently ( Fig. 3) (Li et al., 2017b) . At 1.51 Å resolution, the electron density of the aldehyde moiety of the inhibitor and the surrounding protease residues of bZiPro (C143S) are improved significantly compared to the WT structure. We can observe that the peptide bond between A132 and G133 adopt two conformations and the oxyanion hole is also not formed in bZiPro (C143S) structure ( Fig. 3C, D) . The conformation of the hemiacetal formed between Ac-Lys-Arg-H and S135 can also be refined clearly, allowing the comparison with the ester bond formed between the benzoyl group and S135 ( Fig. 3) .
Unique adduct of the benzoyl moiety to S135
The structure of NS3 and the N-terminal part of NS2B in the complex adopts a similar conformation to those of the linked and unlinked protease in the free form and complexes with substrate and inhibitors.
In the complex, the protease is in the closed conformation in which the C-terminal region (residues 71-87) of NS2B engages with NS3 and forms part of the active site (Fig. 2) . The root-mean-squared deviations (rmsd) of the Cα atoms of observed residues are 0.36 Å (PDB 5GPI, ), 0.26 Å (PDB id 5H4I, ), 0.41 Å (PDB id 5GJ4, ), 0.29 Å (PDB id 5H6V, (Li et al., 2017b) ), and 0.61 Å (PDB id 5LC0, (Lei et al., 2016) ) compared with those of bZiPro in the absence ) and presence of EN300 compound (Li et al., 2017b) , TGKR peptide , Ac-Lys-Arg-H dipeptide (Li et al., 2017b) , and a boronic peptide inhibitor (Lei et al., 2016) , respectively ( Figure S2 , Table   S1 ). To further probe the molecular interactions, the 1 H-15 N-HSQC spectra of bZiPro in the absence and presence of compound 1 were collected and compared. Compared with free protein, bZiPro in complex with compound 1 exhibits profound chemical shift changes in the 1 H-15 N-HSQC spectrum, which clearly indicates their molecular interactions in solution ( Fig. 4A) . In the free ZIKV protease, conformational exchanges between the C-terminal β-hairpin region and NS3 broadened the cross peaks of corresponding residues in the 1 H-15 N-HSQC spectrum . Most of the residues exhibit detectable cross peaks in the 1 H-15 N-HSQC spectrum of the complex and can be unambiguously assigned ( Figure S3 ), suggesting that compound 1 binding stabilizes the protease conformation in solution without direct interactions with residues from NS2B. In addition, compared with the available assignments of free bZiPro, several residues exhibit profound chemical shift perturbations upon inhibitor binding and are limited to the vicinity of the catalytic triad, suggesting that compound 1 binds to the active site ( Fig. 3B) . Although chemical shift difference was observed for the 1 H-15 N spectra of bZiPro in complexes with compound 1 and Ac-Lys-Arg-H, the numbers of the cross peaks of corresponding spectra are similar, indicating that bZiPro is in the closed conformation in both complexes. The observed chemical shift difference is due to the different binding modes of these two inhibitors (Fig. 2, Figure S4 )
Structure and dynamics of bZiPro-compound 1 complex in solution
Compound 1 was titrated into bZiPro and the result showed that several residues such as L98 and L140 were undergoing slow exchanges in NMR time scale ( Fig. 4C, D, E) , indicative of their monovalent and strong bindings in solution. The result agrees well with the conclusion derived from MS analysis and X-ray structure in which compound 1 has covalent interactions with bZiPro, which was also observed for both West Nile and Dengue virus proteases (Koh-Stenta et al., 2015) . 15 N-spin-lattice relaxation rate (R 1 ), spin-spin relaxation rate (R 2 ), and steady-state heteronuclear NOEs (hetNOE) (Kay et al., 1989) values of the complex were obtained to understand its dynamics in solution ( Fig. 5A) . The average ratios of R 2 /R 1 values of N-terminal region of NS2B cofactor region, the β-hairpin region of NS2B, and NS3 excluding flexible residues are very similar (Fig. 5A) . The N-terminal region of the NS2B cofactor is engaged with NS3 regardless of ligand binding while the β-hairpin region of NS2B has different conformations in the absence of an inhibitor. The R 1 and R 2 values of residues from structured regions of NS2B and NS3 in the complex are almost identical, corroborating the conclusion that bZiPro is in the closed conformation and NS2B cofactor forms a stable complex with NS3 ( Fig. 5A) . The termini of NS2B and NS3 are highly dynamic in solution because of the low hetNOEs values. The high mobility of the terminus of NS3 in the absence and presence of compound 1 indicates that the corresponding residues do not form stable interactions with the S prime site of the protease. Other residues in bZiPro of the complex exhibit high hetNOEs (>0.6) values, indicative of their rigid structures in solution. Overall, bZiProcompound 1 forms a stable structure in solution.
The following evidence derived from NMR data support the conclusion obtained from the X-ray structure that the protease in the complex adopts the closed conformation. Firstly, nearly complete resonances from bZiPro in the 1 H-15 N-HSQC spectrum have been assigned, suggesting the uniform structure of the bZiPro in the complex as signal broadening of residues in the free protease was suppressed by inhibitor binding ( Figure S3 ). Similar result was obtained for WNV protease where the closed conformation made it possible to assign most of the resonances in the 1 H-15 N-HSQC spectrum . Secondly, secondary structure analysis using TALOS based on the backbone chemical shifts demonstrates the presence of β-sheet structures in the C-terminal region of the NS2B cofactor region ( Figure S5) . In the open form, the region is unstructured and away from the active site (Jones et al., 2015) . The presence of β-sheet structures in solution suggests the formation of the closed conformation in the complex ( Figure   S5 ). Thirdly, relaxation analysis shows that most residues in bZiPro form rigid structure in solution ( Fig. 5A) and residues from NS2B β-hairpin region exhibit similar dynamic values to those of NS3, which confirms that these two regions form a stable complex in solution. Lastly, unambiguous intermolecular NOEs between amide proton of residues K117 of NS3 and amide protons of V76 and L74 of NS2B are identified, supporting the conclusion that NS2B cofactors forms a complex with NS3 and the complex is in the closed conformation ( Fig. 5B) . In addition, NOEs between amide protons of residues D83 and D79 are identified, which further confirms the presence of the β-hairpin structure in the bZiPro-compound 1 complex ( Fig.   5B, C) .
The integrity of compound 1 is essential for protease binding MS result and X-ray structure indicate that compound 1 reacts with bZiPro in solution as only the benzoyl moiety is covalently-linked to bZiPro. The products of the trans-esterification reaction between bZiPro and compound 1 are the benzoyl moiety linked to S135 of bZiPro and compound 2 ( Fig. 1) . Ultimately, the complex benzoyl-bZiPro might be the subject of a hydrolysis to give a benzoic acid derivative and regenerate the protease S135 hydroxyl while the benzoyl modified bZiPro was stable in solution during our NMR data collection. We then investigated whether benzoic acid and compound 2 can bind to bZiPro, respectively. 1 H-15 N-HSQC spectra of bZiPro in the absence and presence of these two compounds were collected and compared ( Figure S6 ). Interestingly, both compounds do not exhibit obvious interactions with bZiPro as no profound chemical shift differences were observed in the spectra ( Figure S6 ), suggesting that the integrity of compound 1 is required for the activity. Compound 4 has an ester group and a benzoyl moiety and exhibits no obvious interactions with bZiPro ( Figure S6 ), suggesting that compound 1 binding to the active site is prerequisite for the covalent modification and the pyrazole moiety plays an important role in compound 1 binding to bZiPro prior to S135 hydroxyl attack.
Stronger inhibition with a biphenyl moiety from compound 5
To test the idea that modified benzoyl moiety may alter the strength of inhibition, compound 5 with a biphenyl ester rather than phenyl ester group (compound 1) was synthesized. The IC 50 of compound 5 on bZiPro is 0.1 µM (Fig 6A) , exhibiting an improvement over compound 1 whose IC 50 on bZiPro was 1.5 µM.
Molecular weight of bZiPro in complex with compound 5 was subjected to MS analysis. As expected, NS3 exhibits a molecular weight increase of 214.6 Da in the spectrum (Fig. 6B) , which is consistent with the chloro substituted biphenyl-carbonyl modification of NS3. Compound 5 binds to bZiPro as the 1 H-15 N-HSQC of its complex with bZiPro exhibits obvious chemical shift difference from that of the free bZiPro ( Fig. 6C) . Superimposition of the 1 H-15 N-HSQC spectra of bZiPro in complex with compound 1 and compound 5 reveals profound chemical shift differences for numerous residues (Fig. 6D) . The biphenyl group does not fit well in the S1 site based on the obtained structure of bZiPro-compound 1 complex. The observed chemical shift perturbations (CSPs) of several residues may be due to re-orientation of the biphenyl group in the active site upon covalent bond formation as modelled in Fig. 6E . As both compounds 1 and 5 are covalent inhibitors, IC 50 values cannot accurately reflect the differences in inhibitory potential.
To reveal the two inhibition potency matric of the two compounds, we then determined the specificity constants (k inact /K i ). The Compound 5 with a k inact /K i value of 0.143 x 10 6 M -1 s -1 is significantly more potent than compound 1 which has a k inact /K i value of 0.00458 x 10 6 M -1 s -1 (Fig. 7) . The k inact of compound 5 is about 36 times higher than that of compound 1 indicating that compound 5 is able to form adduct with and inactivate the protease at a much faster rate (Fig.7) .
Discussion
Several structures of flaviviral proteases in complex with peptidic inhibitors have been obtained while little structural information for protease in complex with small molecule inhibitors is available (Luo et al., 2015; Nitsche et al., 2014a) . Free linked flaviviral proteases were shown to harbor both open conformation in which the β-hairpin region of the NS2B cofactor is dynamic and stays away from NS3 and closed conformation in which the β-hairpin region is engaged with NS3 and forms part of the active site (Erbel et al., 2006; (Figure S2 ). Our structural study has shown that the free unlinked construct-bZiPro exists in the closed conformation while conformational exchanges are also present in the absence of an inhibitor . It has been well proven that ligand binding can stabilize the closed conformation of proteases by forming interactions with residues from both NS3 and the C-terminal region of NS2B cofactor region . In this study, we demonstrate that compound 1 is able to stabilize the closed conformation of bZiPro by suppressing the conformational exchanges (Fig. 3) . Interestingly, compound 1 binding to bZiPro causes an increase in molecular mass of NS3 by 104 Da, which is due to the covalent modification of S135 by the benzoyl moiety (Fig. 1, Fig. 2) .
Based on the X-ray crystal structure, only part of S1 pocket is occupied by the benzoyl moiety (Fig. 2) . The remaining hydroxyl-pyrazole derivative from compound 1 falls off the protease (Fig. 2) . The integrity of compound 1 is essential for protease binding as the derived fragments from compound 1 exhibit no clear interactions with protease ( Figure S6 ). Recently, we reported the crystal structure of bZiPro in complex with a fragment (EN300) . This fragment interacts with part of the S1 pocket and overlap with the guanidinium group of P1 Arg, which is different from that of the benzoyl moiety ( Fig. 2   and Fig. 3) . EN300 binding to bZiPro does not suppress the conformational exchanges as the missing cross peaks in the free bZiPro are still not observed in the bZiPro-EN300 complex . It is interesting that modification of the side chain of S135 with a benzoyl group (M.W. 104 Da) can stabilize the closed conformation of the protease (Fig. 2, Fig. 4) . Such result suggests that suppressing the conformational exchanges between NS2B and NS3 by an inhibitor does not require direct interactions between the inhibitor and NS2B.
We have confirmed that compound 1 and compound 5 exhibit micro to nano-molar IC 50 s against bZiPro ( Fig. 1, Fig. 6 and Fig. 7) . Although compound 1 exhibits a weaker IC 50 against bZiPro than WNV and DENV proteases, modification of compound 1 generates compound 5 which can also covalently modify bZiPro with much improved inhibition potency ( Fig. 6 and Fig. 7) . As compound 2 and compound 3 representing the corresponding fragments of compound 1 exhibit no obvious interactions with bZiPro ( Figure S6 ), we speculate the following steps involved in inhibition of bZiPro by compounds 1. The intact inhibitor first recognizes and binds to protease active site. Benzoylation of bZiPro on the side chain of S135 is the result of the nucleophilic attack of S135 hydroxyl on the inhibitor ester, which occurs after compound binding.
The formation of a covalent bond between the benzoyl moiety of compound 1 and the side chain of S135 stabilizes the closed conformation. The hydroxyl pyrazole group of compound 1 falls off from the protease.
It is encouraging to identify this type of inhibitors because they are small molecules which might be able to overcome the cell penetrating problems that are encountered for substrate-derived inhibitors. It has also been noted that this type of inhibitors are not stable in solution because they can be hydrolyzed in buffer, which limits their further development. Nonetheless, our current study provides a piece of evidence that small molecular weight inhibitors can be developed against ZIKV protease while further effort is still needed due to the limitation of this type of inhibitors.
Structure-based drug design is a powerful strategy in target-based drug discovery. Knowing protein-ligand structural information is helpful for further inhibitor design. In this study, we characterized proteininhibitor interactions using solution NMR spectroscopy, MS and X-ray crystallography. It is clear that the structures of NS2B and NS3 remain almost unchanged in the presence of different types of inhibitors such as fragment , substrate or peptidic inhibitors (Lei et al., 2016; Li et al., 2017b) . The close conformation of flavivirus protease should be used in structure-based drug design.
Despite the stability issues of compound 1 in solution, current study provides structural information for bZiPro linked to a benzoyl moiety (Fig. 2) . Our biochemical assay clearly demonstrates the inhibitory efforts of this type of inhibitors on protease activity, suggesting that it is possible to develop small molecule protease inhibitors. Compared with dengue and West Nile proteases, structure-based drug design may be a powerful tool to design potent inhibitors against Zika protease as numerous structures of the protease in the absence and presence of inhibitors are available (Kang et al., 2017) (Table S1 ).
In summary, we use X-ray crystallography and MS to demonstrate that compound 1 forms covalent interactions with bZiPro and the benzolated protease is in the closed conformation. The integrity of the inhibitor is essential for the activity and protease binding. Modification of compound 1 generates a more potent inhibitor-compound 5. Current study provides an example showing that the active site small molecule inhibitors are available while more chemical modifications might be required to improve the potency of the inhibitors. Figures S1-S6 and Table S1 . D. Several residues undergo slow exchanges. Several residues such as L78 and L140 exhibit multiple peaks when protein to ligand ratio is more than 1. E. Several residues exhibit cross peaks in the spectra when bZiPro is mixed with compound 1. 
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Materials and methods
Protein expression and purification
The bZiPro variant was produced by using synthesized codon optimized cDNA sequence of NS2B-NS3 (Genescript) as template. Two separate fragments as 45-96 of NS2B and 1-177 of NS3 were selected with Cys143Ser mutation site designed in primers. The Forward primer used as GGATCTCCGATCCTCGACAAGTCAGGACGTGTGATCGGACTTTATGGC, and Reverse as GCCATAAAGTCCGATCACACGTCCTGACTTGTCGAGGATCGGAGATCC. The fragment was amplified by KODFX Neo of TOYOBO. The PCR product was transformed to DH5 α. The positive clones were selected and plasmids were extracted after overnight culture. The plasmid with Cys143Ser mutation was verified by sequencing and expressed for further purification.
X-ray structure determination
Compound 1 was dissolved in dimethyl sulfoxide to a 100 mM stock solution. The bZiProC143S protein crystallization was determined as described Diffraction data was collected at Australian Synchrotron (Clayton, Victoria) by using the MX1 beamline.
IMOSFLM Software was used for diffraction intensities integration (Battye et al., 2011) . Data collection statistics was analyzed using POINTLESS and AIMLESS function of CCP4 suite (Evans, 2007 (Evans, , 2011 Potterton et al., 2003) , as listed in Table 1 . Refinement was proceed by Phenix (Adams et al., 2010; Afonine et al., 2012; Headd et al., 2012) and Coot (Emsley and Cowtan, 2004; Emsley et al., 2010) . PyMOL was used for generate figures (PyMOL The PyMOL Molecular Graphics System).
NMR experiments
Isotope-labeled bZiPro were typically concentrated to 0.8 to 1.0 mM in a buffer that contained 20 mM HEPES pH7.3, 150 mM NaCl and 1 mM DTT. All NMR experiments were performed at 298 K on a Bruker
Avance II 700-MHz spectrometer. Sequential assignment was obtained using transverse relaxationoptimized spectroscopy (TROSY) Salzmann et al., 1998) -based experiments including 2D-1 H-15 N-HSQC, 3D-HNCACB, 3D-HNCOCACB, 3D-HNCA, 3D-HNCO and NOESY-TROSY (with a mixing time of 120 ms). To identify the NOEs between protein and compound 1, an F1-13 C/ 15 N-filtered and F2-15 N-edited NOESY experiment (mixing time 200 ms) was collected using a 15 N, 13 C, and 2 H-labeled bZiPro in complex with compound 1. All the pulse programs used in this study are from the standard pulse library (Topspin 2.1, Bruker). The NMR data were processed with the NMRPipe (Delaglio et al., 1995) and
Topspin 2.1. Data were visualized with NMRView (Johnson, 2004) and Cara. Protein secondary structures of the complex were determined using TALOSN (Shen et al., 2009) . The 15 N relaxation parameters including 15 N-R 1 , R 2 and hetNOE (Kay et al., 1989) were obtained from the standard relaxation experiments.
Mass spectrometry (MS) analysis
Modification of protease by the compound was analyzed using MS as previously described (Koh-Stenta et al., 2015) . Purified bZiPro was diluted to 20 µM using the NMR buffer. Compound from the stock was mixed with bZiPro with a compound-protein ration of 4:1 at room temperature for 1 h. DMSO was used as the reference. Samples were subjected to analysis and the molecular weight of protease was determined. Two major peaks corresponding to NS2B cofactor region and NS3 protease region were observed in the spectra because there is no linker present in these two polypeptides. Increase of the molecular weight of NS3 indicates the covalent modification by the compound. S135 of NS3 is responsible for the covalent linage with compound 1, verified by mutagenesis study (Koh-Stenta et al., 2015) .
Inhibition assays
Inhibition assay was carried out using the method described previously . Briefly, synthesized inhibitors were dissolved in DMSO. The assay buffer contained 20 mM Tris pH 8.5, 10% glycerol, 0.01% Triton X-100 (Leung et al., 2001) . Protease was diluted to 3 nM and incubated with different amounts of inhibitors in the assay buffer for 30 min at a final DMSO concentration of 0.3%.
Substrate Bz-nKRR-AMC was added to a final concentration of 30 μM. The fluorescence intensities of the mixtures were monitored at 60 second intervals over 10 min using a Cytation 3 Mulitmode plate reader (BioTek). The reaction and monitor temperature was at 37 o C. The excitation and emission wavelengths were 380 nm and 460 nm, respectively. All the assays were carried out in Corning® 96-well plates as triplicates. The half maximal inhibitory concentration (IC 50 ) of an inhibitor was determined using GraphPad Prism version 5.0 (GraphPad Software, La Jolla California, USA).
To determine the k inact /K i of compound 1 N relaxation parameters including 15 N-R 1 (1/T 1 ), R 2 (1/T 2 ) and hetNOE (Kay et al., 1989) were collected at 25 °C for aforementioned sample as we described previously (Li et al., 2017b) . For the R 1 measurement, several 1 H-15 N-HSQC experiments with different relaxation delays of 100, 200, 400, 600, 800, 1200, 1600, 2000 , 2500 and 3000 ms were collected and analyzed, respectively. For the R 2 measurement, 1 H-15 N-HSQC spectra with relaxation delays of 17, 34, 51, 68, 85, 102, 119, 136 and 153 ms were obtained and analyzed, respectively. The hetNOEs were obtained using two datasets that were collected with and without initial proton saturation for a period of 3 s (Gayen et al., 2011) . The R 1, R 2 and hetNOE values were calculated using NMRView (Johnson, 2004) . The titration experiments were analyzed and the binding constants were obtained using NMRView Java version (Johnson, 2004) .
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Coordinates and structure factors have been deposited in the Protein Data Bank under accession code 5YOF and 5YOD. Assignment of protease-compound 1 complex has been deposited in the Biological 
